PIK3CA and colorectal carcinoma: Given the roles of the PI3K and MAPK pathways in CRC, the rationale for combining these inhibitors is based on their potential to overcome resistance and provide enhanced therapeutic benefits, especially in CRC subpopulations with relevant genetic mutations.